News | December 12, 2025
FDA nods spotlight precision oncology platforms as market surges towards $212 billion by 2034
The U.S. oncology market is projected to soar from $81 billion in 2025 to $212 billion by 2034
The U.S. oncology market is projected to soar from $81 billion in 2025 to $212 billion by 2034
Harnessing advanced data analysis for early detection, prevention and better outcomes
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Bridging the gap between histopathology and molecular pathology
The two companies will work together for the Prospective Evaluation of OrionAI – a revolutionary AI-based Diagnostic Assistant for Histological Examination of a variety of solid tumours beginning with Head and Neck Squamous Cell Carcinoma (HNSCC) Cancer
The acquisition positions Roche more aggressively in digital pathology and precision diagnostics capabilities
Collaboration to accelerate mRNA neoantigen therapy development for colorectal and pancreatic cancers using advanced immunology and dark genome insights
The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
A major push to sharpen the future of cancer treatment is underway
Subscribe To Our Newsletter & Stay Updated
